Compare ACFN & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | TELA |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 36.7M |
| IPO Year | N/A | 2019 |
| Metric | ACFN | TELA |
|---|---|---|
| Price | $19.65 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 18.5K | ★ 63.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,300,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | ★ 18.56 |
| 52 Week Low | $12.42 | $0.67 |
| 52 Week High | $33.00 | $2.48 |
| Indicator | ACFN | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 52.67 |
| Support Level | $16.12 | $0.67 |
| Resistance Level | $20.85 | $0.93 |
| Average True Range (ATR) | 1.44 | 0.09 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 38.66 | 81.37 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. It operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.